Phathom Pharmaceuticals Completes Patient Enrollment in Phas

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Canada , Nick Benedetto , Azmi Nabulsi , Linkedin , Twitter , Consensus Group , Nasdaq , Company Annual Report On Form , Exchange Commission , Phathom Pharmaceuticals Inc , Phathom Pharmaceuticals , Dosing Phase , New Drug Application , Chief Operating Officer , Non Erosive Gastroesophageal Reflux Disease , Cutaneous Adverse Reactions , Diagnostic Investigations , Neuroendocrine Tumors , Precautions Due , Clarithromycin Component , Fetal Toxicity , Prescribing Information , Hepatic Impairment , Annual Report , Private Securities Litigation Reform Act ,